4 products found
Aphios Corporation Products
-
Infectious Disease Therapeutic
Infectious diseases are a scourge to humanity dating back to our prehistoric ancestors. In the last millennium (peaking between AD 1348 and AD 1350), the black plague – caused by the bacterium Yersiva pestis and exacerbated by poor sanitary conditions – devastated Europe, killing 30-60% of the population. Smallpox traced back to 1,000 BC in Egyptian mummies, was introduced to the Americas by Spanish conquistadors in the 15th century, where it decimated 80-90% of the Amerindian populations. Smallpox is thought to be responsible for 300-500 million deaths in the 20th century.
-
Aphios - Model APP-0205, APP-309 - Anti-Influenza Therapeutics
Flu – A Serious, Deadly Disease with Pandemic Potential. In 1918, the Spanish flu (H1N1 influenza virus) rapidly killed 50 to 100 million people worldwide, affecting one of every five Americans. Today, influenza remains a common and serious respiratory illness that contributes to the reduction of quality of life and results in a significant loss of manpower hours each year. Every year, 40 million Americans catch the flu and 20,000 to 40,000 ...
-
Aphios - Vaccine Adjuvant Technology
Vaccination is the most cost-effective tool for the control and prevention of infectious diseases. However, multiple inoculations are often required to achieve desirable protection even with potent antigens. In order to increase the therapeutic efficiency of such vaccines, adjuvants are used with vaccines to augment the immune response. There are several types of adjuvants with different modes of action. Adjuvants form a depot of antigen at the site of ...
-
Aphios - Model APH-0812 - Combination Therapy
A combination therapy consisting of PKC agonists with or without HDAC inhibitors, designed to reactivate latent HIV reservoirs so that HIV can be eliminated by antiviral therapy and eradicated from the body. HIV Latency: Although highly active antiretroviral therapy (HAART) is undoubtedly a lifesaving therapy for millions of AIDS patients, the persistence of latent HIV-infected cellular reservoirs represents a major hurdle to virus eradication. Latently ...
-
Model APH-0202 - Oral Nanoformulation Containing Betulinic Acid
An orally bioavailable nanoformulation of betulinic acid that works as an HIV maturation inhibitor. APH-0202 is an oral nanoformulation containing betulinic acid. A pentacyclic triterpene, betulinic acid is a component of the bark of the white birch tree, Betula alba. Phospholipid nanosomes can be utilized to enhance the formulation and efficacy of betulinic acid. Oral bioavailability can be enhanced by nanoencapsulating betulinic acid nanosomes and/or ...